Sidra Medicine launches new child disease treatments
Sadria Oncology has successfully introduced two new specialized treatments for children with high-risk neuroblastoma for the first time in the Gulf Cooperation Council countries and Qatar. This achievement was made possible through intensive preparation in collaboration between the oncology and stem cell transplantation teams. The two medications, Naxitamab and Dinutuximab Beta, are monoclonal antibody-based therapies used to combat this cancer that originates in the nervous system of children, predominantly affecting those under five years old. The treatments were administered to two patients following stem cell transplants, marking a significant advancement in treatment options at Sadria Oncology. This represents an important milestone in providing high-quality care for children with cancer in Qatar.
Notice: This Is an AI-Generated Summary
Comments (0)